The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes
Open accessAbstract
BACKGROUND & AIMS Cholangiocarcinoma, the second most common liver cancer, can be classified as intra-hepatic cholangiocarcinoma (ICC) or extrahepatic cholangiocarcinoma. We performed an integrative genomic analysis of ICC samples from a large series of patients. METHODS We performed a gene expression profile, high-density single-nucleotide polymorphism array, and mutation analyses using formalin-fixed ICC samples from 149 patients. Associations with clinicopathologic traits and patient outcomes were examined for 119 cases. Class discovery was based on a non-negative matrix factorization algorithm and significant copy number variations were identified by GISTIC analysis. Gene set enrichment analysis was used to identify signaling pathways activated in specific molecular classes of tumors, and to analyze their genomic overlap with hepatocellular carcinoma (HCC). RESULTS We identified 2 main biological classes of ICC. The inflammation class (38% of ICCs) is characterized by activation of inflammatory signaling pathways, overexpression of cytokines, and STAT3 activation. The proliferation class (62%) is characterized by activation of oncogenic signaling pathways (including RAS, mitogen-activated protein kinase, and MET), DNA amplifications at 11q13.2, deletions at 14q22.1, mutations in KRAS and BRAF, and gene expression signatures previously associated with poor outcomes for patients with HCC. Copy number variation– based clustering was able to refine these molecular groups further. We identified high-level amplifications in 5 regions, including 1p13 (9%) and 11q13.2 (4%), and several focal deletions, such as 9p21.3 (18%) and 14q22.1 (12% in coding regions for the SAV1 tumor suppressor). In a complementary approach, we identified a gene expression signature that was associated with reduced survival times of patients with ICC; this signature was enriched in the proliferation class (P < .001). CONCLUSIONS We used an integrative genomic analysis to identify 2 classes of ICC. The proliferation class has specific copy number alterations, many features of the poor-prognosis signatures for HCC, and is associated with worse outcome. Different classes of ICC, based on molecular features, therefore might require different treatment approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,406
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
Metagenes and molecular pattern discovery using matrix factorization
Brunet, J.-P., Tamayo, P., Golub, T. R., & Mesirov, J. P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308531101 · Cited by 2,183
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets
Boyault, S., Rickman, D. S., de Reyniès, A., Balabaud, C., Rebouissou, S., Jeannot, E., Hérault, A., Saric, J., Belghiti, J., Franco, D., et al. (2007) · Hepatology · doi:10.1002/hep.21467 · Cited by 1,258
Hoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238
Self-citationSafety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
Verstovsek, S., Kantarjian, H., Mesa, R. A., Pardanani, A. D., Cortes-Franco, J., Thomas, D. A., Estrov, Z., Fridman, J. S., Bradley, E. C., Erickson-Viitanen, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002028 · Cited by 1,164
Khan, S. A., Thomas, H. C., Davidson, B. R., & Taylor-Robinson, S. D. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67530-7 · Cited by 1,042
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling
Lee, J.-S., Chu, I.-S., Heo, J., Calvisi, D. F., Sun, Z., Roskams, T., Durnez, A., Demetris, A. J., & Thorgeirsson, S. S. (2004) · Hepatology · doi:10.1002/hep.20375 · Cited by 922
IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway
Wang, L., Yi, T., Kortylewski, M., Pardoll, D. M., Zeng, D., & Yu, H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090207 · Cited by 842
de Jong, M. C., Nathan, H., Sotiropoulos, G. C., Paul, A., Alexandrescu, S., Marques, H., Pulitano, C., Barroso, E., Clary, B. M., Aldrighetti, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6519 · Cited by 729
Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver
Lu, L., Li, Y., Kim, S. M., Bossuyt, W., Liu, P., Qiu, Q., Wang, Y., Halder, G., Finegold, M. J., Lee, J.-S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911427107 · Cited by 721
Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma
Chiang, D. Y., Villanueva, A., Hoshida, Y., Peix, J., Newell, P., Minguez, B., LeBlanc, A. C., Donovan, D. J., Thung, S. N., Solé, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0742 · Cited by 719
Self-citationCholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment†
Blechacz, B., & Gores, G. J. (2008) · Hepatology · doi:10.1002/hep.22310 · Cited by 681
Cancer genomics: from discovery science to personalized medicine
Chin, L., Andersen, J. N., & Futreal, P. A. (2011) · Nature Medicine · doi:10.1038/nm.2323 · Cited by 644
Changing international trends in mortality rates for liver, biliary and pancreatic tumours
Khan, S. A., Taylor-Robinson, S. D., Toledano, M. B., Beck, A., Elliott, P., & Thomas, H. C. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00297-0 · Cited by 570
Andersen, J. B., Spee, B., Blechacz, B. R., Avital, I., Komuta, M., Barbour, A., Conner, E. A., Gillen, M. C., Roskams, T., Roberts, L. R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.005 · Cited by 552
Lee, K.-P., Lee, J.-H., Kim, T.-S., Kim, T.-H., Park, H.-D., Byun, J.-S., Kim, M.-C., Jeong, W.-I., Calvisi, D. F., Kim, J.-M., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912203107 · Cited by 493
Liver stem cells and their implication in hepatocellular and cholangiocarcinoma
Roskams, T. (2006) · Oncogene · doi:10.1038/sj.onc.1209558 · Cited by 422
Krambeck, A. E., Thompson, R. H., Dong, H., Lohse, C. M., Park, E. S., Kuntz, S. M., Leibovich, B. C., Blute, M. L., Cheville, J. C., & Kwon, E. D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600937103 · Cited by 305
Oishi, N., Kumar, M. R., Roessler, S., Ji, J., Forgues, M., Budhu, A., Zhao, X., Andersen, J. B., Ye, Q.-H., Jia, H.-L., et al. (2012) · Hepatology · doi:10.1002/hep.25890 · Cited by 260
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies
Sia, D., Tovar, V, Moeini, A., & Llovet, J. M. (2013) · Oncogene · doi:10.1038/onc.2012.617 · Cited by 235
Self-citationIsomoto, H., Kobayashi, S., Werneburg, N. W., Bronk, S. F., Guicciardi, M. E., Frank, D. A., & Gores, G. J. (2005) · Hepatology · doi:10.1002/hep.20966 · Cited by 227
Wehbe, H., Henson, R., Meng, F., Mize-Berge, J., & Patel, T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2130 · Cited by 224
Sustained IL-6/STAT-3 Signaling in Cholangiocarcinoma Cells Due to SOCS-3 Epigenetic Silencing
Isomoto, H., Mott, J. L., Kobayashi, S., Werneburg, N. W., Bronk, S. F., Haan, S., & Gores, G. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.10.037 · Cited by 219
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial
Bengala, C., Bertolini, F., Malavasi, N., Boni, C., Aitini, E., Dealis, C., Zironi, S., Depenni, R., Fontana, A., Del Giovane, C., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605458 · Cited by 216
Surgical Management of Intrahepatic Cholangiocarcinoma - A Population-Based Study
Tan, J. C. C., Coburn, N. G., Baxter, N. N., Kiss, A., & Law, C. H. L. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9627-x · Cited by 213
Blechacz, B. R. A., & Gores, G. J. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.11.003 · Cited by 212
Genetics of Biliary Tract Cancers and Emerging Targeted Therapies
Hezel, A. F., Deshpande, V., & Zhu, A. X. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4787 · Cited by 210
Tannapfel, A., Benicke, M., Katalinic, A., Uhlmann, D., Köckerling, F., Hauss, J., & Wittekind, C. (2000) · Gut · doi:10.1136/gut.47.5.721 · Cited by 193
Identification of a Cholangiocarcinoma-Like Gene Expression Trait in Hepatocellular Carcinoma
Woo, H. G., Lee, J.-H., Yoon, J.-H., Kim, C. Y., Lee, H.-S., Jang, J. J., Yi, N.-J., Suh, K.-S., Lee, K. U., Park, E. S., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2823 · Cited by 190
Intrahepatic Cholangiocarcinoma: New Insights in Pathology
Sempoux, C., Jibara, G., Ward, S., Fan, C., Qin, L., Roayaie, S., Fiel, M. I., Schwartz, M., & Thung, S. (2011) · Seminars in Liver Disease · doi:10.1055/s-0031-1272839 · Cited by 186
Self-citationRossi, J.-F., Négrier, S., James, N. D., Kocak, I., Hawkins, R., Davis, H., Prabhakar, U., Qin, X., Mulders, P., & Berns, B. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605872 · Cited by 166
Yang, B., House, M. G., Guo, M., Herman, J. G., & Clark, D. P. (2004) · Modern Pathology · doi:10.1038/modpathol.3800287 · Cited by 157
Quandt, D., Fiedler, E., Boettcher, D., Marsch, W. C., & Seliger, B. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2268 · Cited by 139
Ror1 Is a Pseudokinase That Is Crucial for Met-Driven Tumorigenesis
Gentile, A., Lazzari, L., Benvenuti, S., Trusolino, L., & Comoglio, P. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2662 · Cited by 138
Terada, T., Nakanuma, Y., & Sirica, A. E. (1998) · Human Pathology · doi:10.1016/s0046-8177(98)90229-5 · Cited by 133
Jinawath, N., Chamgramol, Y., Furukawa, Y., Obama, K., Tsunoda, T., Sripa, B., Pairojkul, C., & Nakamura, Y. (2006) · Hepatology · doi:10.1002/hep.21330 · Cited by 130
Advances in the diagnosis, evaluation and management of cholangiocarcinoma
Singh, P., & Patel, T. C. (2006) · Current Opinion in Gastroenterology · doi:10.1097/01.mog.0000218967.60633.64 · Cited by 79
Early Accelerated Approval for Highly Targeted Cancer Drugs
Chabner, B. A. (2011) · New England Journal of Medicine · doi:10.1056/nejmp1100548 · Cited by 79
Microsatellite instability and alternative genetic pathway in intrahepatic cholangiocarcinoma
Momoi, H., Itoh, T., Nozaki, Y., Arima, Y., Okabe, H., Satoh, S., Toda, Y., Sakai, E., Nakagawara, K.-I., Flemming, P., et al. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00106-4 · Cited by 57
ROR1 is a pseudokinase that is crucial for MET-driven tumorigenesis
Lazzari, L., Gentile, A., Benvenuti, S., Trusolino, L., & Comoglio, P. M. (2013) · BMC Proceedings · doi:10.1186/1753-6561-7-s2-p43 · Cited by 50
Wang, A., Yoon, S. Y., Oh, J., Jeon, Y.-J., Kim, M., Kim, J., Byun, S.-S., Yang, J. O., Kim, J. H., Kim, D., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.04.175 · Cited by 50
Clinical Significance of Cell Cycle–and Apoptosis-Related Markers in Biliary Tract Cancer
Karamitopoulou, E., Tornillo, L., Zlobec, I., Cioccari, L., Carafa, V., Borner, M., Schaffner, T. J., Brunner, T., Diamantis, I. D., Zimmermann, A., et al. (2008) · American Journal of Clinical Pathology · doi:10.1309/ajcp35fdcavanwmm · Cited by 46
A detailed transcriptional map of the chromosome 12p12 tumour suppressor locus
Montpetit, A., Boily, G., & Sinnett, D. (2002) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5200766 · Cited by 42
Zhang, H., Gorn, M., Smith, K., Graham, A., Lau, K. K. W., & Bicknell, R. (1999) · Angiogenesis · doi:10.1023/a:1009085422384 · Cited by 33
Stokes, A., Drozdov, I. A., Guerra, E. N. S., Ouzounis, C., Warnakulasuriya, S., Gleeson, M. J., McGurk, M., Tavassoli, M., & Odell, E. W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024503 · Cited by 15
Cited by
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Banales, J. M., Marin, J. J. G., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., Cardinale, V., Carpino, G., Andersen, J. B., Braconi, C., et al. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0310-z · Cited by 2,411
“In this regard, aberrant EGFR , ERBB2 and MET RTK expression has been found in different CCA subclasses that are associated with worse prognosis 8,110 .”
InfluentialSelf-citationRazumilava, N., & Gores, G. J. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61903-0 · Cited by 1,729
Cholangiocarcinoma — evolving concepts and therapeutic strategies
Ilyas, S. I., Khan, S. A., Hallemeier, C. L., Kelley, R. K., & Gores, G. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.157 · Cited by 1,626
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
Bridgewater, J., Galle, P. R., Khan, S. A., Llovet, J. M., Park, J.-W., Patel, T., Pawlik, T. M., & Gores, G. J. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.021 · Cited by 1,511
Self-citationBanales, J. M., Cardinale, V., Carpino, G., Marzioni, M., Andersen, J. B., Invernizzi, P., Lind, G. E., Folseraas, T., Forbes, S. J., Fouassier, L., et al. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.51 · Cited by 1,376
Metadata
- Authors
- Sia, D., Hoshida, Y., Villanueva, A., Roayaie, S., Ferrer, J., Tabak, B., Peix, J., Sole, M., Tovar, V., Alsinet, C., Cornella, H., Klotzle, B., Fan, J., Cotsoglou, C., Thung, S. N., Fuster, J., Waxman, S., Garcia–Valdecasas, J. C., Bruix, J., Schwartz, M. E., Beroukhim, R., Mazzaferro, V., & Llovet, J. M.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2013-04
- Volume
- 144
- Issue
- 4
- Pages
- 829-840
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2001008402
- Cited by
- 575
- References
- 53
- FWCI
- 35.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.